William G. Nelson, M.D., Ph.D.
Dr. Nelson is the Marion I. Knott Professor of Oncology and Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He currently holds Professorships in Oncology, Medicine, Pharmacology, Pathology, Radiation Oncology, Urology, and Environmental Health Sciences. His laboratory discovered one of the first epigenetically-silenced genes in human cancer, GSTP1, inactivated in nearly all prostate cancer cases. GSTP1 DNA methylation assays approved by the US Food and Drug Administration serve as adjuncts for prostate cancer diagnosis, the first epigenetic laboratory tests in common use. Dr. Nelson and colleagues also identified the major precursor to prostate cancer, ‘proliferative inflammatory atrophy.’
Outside of Johns Hopkins, Dr. Nelson has also become a recognized leader in cancer research, organizing national and international meetings in cancer health disparities, cancer prevention, and prostate cancer, serving on the Board of the V Foundation, as a Scientific Co-Chair for Stand Up 2 Cancer, on the Scientific Advisory Board for the Prostate Cancer Foundation, and as a Co-Chair of the National Cancer-Institute Translational Research Working Group, and working as Executive Editor of Cancer Today and a Senior Editor of Cancer Research. Owner of seven issued patents, he is a co-founder of Digital Harmonics, a Board Member of Armis Biopharma, and an Advisory Board Member of Abbvie and of Proquest Investments.